MX2013003695A - Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida. - Google Patents
Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.Info
- Publication number
- MX2013003695A MX2013003695A MX2013003695A MX2013003695A MX2013003695A MX 2013003695 A MX2013003695 A MX 2013003695A MX 2013003695 A MX2013003695 A MX 2013003695A MX 2013003695 A MX2013003695 A MX 2013003695A MX 2013003695 A MX2013003695 A MX 2013003695A
- Authority
- MX
- Mexico
- Prior art keywords
- component
- arylamino
- combinations
- aryl sulfonamide
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención se relaciona con: combinaciones de: Componente A: uno o más compuestos de difenil urea sustituida con omega-carboxiarilo de la fórmula general (I), o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable de los mismos; Componente B: uno o más compuestos de N-(2-arilamino) arilsulfonamida de la fórmula general (II), o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable de los mismos; y, opcionalmente, Componente C: uno o más agentes farmacéuticos adicionales; en donde opcionalmente algunos o todos los componentes se encuentran en la forma de una formulación farmacéutica lista para usar administrada de manera simultánea, concurrente, separada o sucesiva de manera d ependiente entre sí por la ruta oral, intravenosa, tópica, instilaciones locales, intraperitoneal o nasal; uso de dichas combinaciones en la preparación de un medicamento para el tratamiento o la profilaxis de cáncer; y un conjunto de elementos que comprende una combinación tal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10185800 | 2010-10-01 | ||
PCT/EP2011/067041 WO2012041987A1 (en) | 2010-10-01 | 2011-09-29 | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013003695A true MX2013003695A (es) | 2013-05-20 |
Family
ID=44719990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013003695A MX2013003695A (es) | 2010-10-01 | 2011-09-29 | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida. |
Country Status (25)
Country | Link |
---|---|
US (1) | US9381177B2 (es) |
EP (1) | EP2621486A1 (es) |
JP (1) | JP2013538840A (es) |
KR (1) | KR20130099117A (es) |
CN (1) | CN103228274A (es) |
AP (1) | AP2013006834A0 (es) |
AU (1) | AU2011310532B2 (es) |
BR (1) | BR112013007835A2 (es) |
CA (1) | CA2813069A1 (es) |
CL (1) | CL2013000881A1 (es) |
CO (1) | CO6690783A2 (es) |
CR (1) | CR20130147A (es) |
CU (1) | CU20130050A7 (es) |
DO (1) | DOP2013000070A (es) |
EA (1) | EA201300420A1 (es) |
EC (1) | ECSP13012538A (es) |
GT (1) | GT201300085A (es) |
IL (1) | IL225400A0 (es) |
MA (1) | MA34553B1 (es) |
MX (1) | MX2013003695A (es) |
NZ (1) | NZ608584A (es) |
PE (1) | PE20140165A1 (es) |
SG (1) | SG189038A1 (es) |
UA (1) | UA112163C2 (es) |
WO (1) | WO2012041987A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877933B2 (en) * | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2015527874A (ja) * | 2012-05-31 | 2015-09-24 | バイエル ファーマ アクチエンゲゼルシャフト | 肝細胞癌(hcc)患者の治療の有効な応答を決定するためのバイオマーカー |
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
US20170273922A1 (en) * | 2014-10-03 | 2017-09-28 | The Royal Institution For The Advacement Of Learning/Mcgill University | Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders |
BR112018008714A2 (pt) | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2 |
CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
CN110719781A (zh) | 2017-02-14 | 2020-01-21 | 效应治疗股份有限公司 | 取代的哌啶MnK抑制剂及其相关方法 |
CN107417604A (zh) * | 2017-07-25 | 2017-12-01 | 新发药业有限公司 | 4‑取代吡啶‑2‑甲酰胺化合物及其制备方法与应用 |
EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | CRYSTALLINE FORMS OF MNK INHIBITORS |
WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CZ302846B6 (cs) * | 1999-01-13 | 2011-12-14 | Bayer Healthcare Llc | Difenylová mocovina substituovaná omega-karboxyarylovou skupinou, její použití a farmaceutická kompozice jí obsahující |
MXPA04005137A (es) | 2001-12-03 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuestos de aril urea en combinacion con otros agentes citostaticos para el tratamiento de canceres humanos. |
US6803315B2 (en) | 2002-08-05 | 2004-10-12 | International Business Machines Corporation | Method for blocking implants from the gate of an electronic device via planarizing films |
MXPA05001808A (es) | 2002-09-30 | 2005-08-16 | Bayer Pharmaceuticals Corp | Derivados de azol-pirimidina condensados. |
ES2305808T3 (es) * | 2003-05-20 | 2008-11-01 | Bayer Healthcare Llc | Diarilureas con actividad inhibidora de quinasas. |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
DE102004064002B4 (de) | 2004-08-04 | 2019-05-09 | Continental Automotive Gmbh | System zum Überwachen einer Sensorvorrichtung |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
UA90691C2 (en) | 2004-09-29 | 2010-05-25 | Баер Шеринг Фарма Акциенгезельшафт | Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
EA200701930A1 (ru) | 2005-03-10 | 2008-02-28 | Байер Фармасьютикалс Корпорейшн | Производные пиримидина для лечения гиперпролиферативных нарушений |
US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
SI1912636T1 (sl) | 2005-07-21 | 2014-08-29 | Ardea Biosciences, Inc. | N-(arilamino)-sulfonamidni inhibitorji MEK |
AU2006272837B2 (en) * | 2005-07-21 | 2012-08-23 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of MEK |
JP5084736B2 (ja) | 2005-11-10 | 2012-11-28 | バイエル・ファルマ・アクチェンゲゼルシャフト | 肺高血圧を処置するためのジアリールウレア |
PL1948176T3 (pl) | 2005-11-10 | 2011-05-31 | Bayer Schering Pharma Ag | Diarylomoczniki do leczenia nadciśnienia płucnego |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
JP5479337B2 (ja) | 2007-07-30 | 2014-04-23 | アルディア バイオサイエンス,インク. | Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用 |
JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Mek阻害剤に対する耐性を付与するmek突然変異 |
-
2011
- 2011-09-29 KR KR1020137010490A patent/KR20130099117A/ko not_active Application Discontinuation
- 2011-09-29 UA UAA201305238A patent/UA112163C2/uk unknown
- 2011-09-29 CA CA2813069A patent/CA2813069A1/en not_active Abandoned
- 2011-09-29 US US13/877,204 patent/US9381177B2/en not_active Expired - Fee Related
- 2011-09-29 AP AP2013006834A patent/AP2013006834A0/xx unknown
- 2011-09-29 MA MA35781A patent/MA34553B1/fr unknown
- 2011-09-29 WO PCT/EP2011/067041 patent/WO2012041987A1/en active Application Filing
- 2011-09-29 NZ NZ608584A patent/NZ608584A/en not_active IP Right Cessation
- 2011-09-29 JP JP2013530737A patent/JP2013538840A/ja active Pending
- 2011-09-29 MX MX2013003695A patent/MX2013003695A/es unknown
- 2011-09-29 CN CN2011800572946A patent/CN103228274A/zh active Pending
- 2011-09-29 BR BR112013007835A patent/BR112013007835A2/pt not_active Application Discontinuation
- 2011-09-29 PE PE2013000697A patent/PE20140165A1/es not_active Application Discontinuation
- 2011-09-29 AU AU2011310532A patent/AU2011310532B2/en not_active Ceased
- 2011-09-29 EP EP11763694.4A patent/EP2621486A1/en not_active Withdrawn
- 2011-09-29 EA EA201300420A patent/EA201300420A1/ru unknown
- 2011-09-29 SG SG2013020920A patent/SG189038A1/en unknown
-
2013
- 2013-03-21 IL IL225400A patent/IL225400A0/en unknown
- 2013-04-01 GT GT201300085A patent/GT201300085A/es unknown
- 2013-04-01 CL CL2013000881A patent/CL2013000881A1/es unknown
- 2013-04-01 DO DO2013000070A patent/DOP2013000070A/es unknown
- 2013-04-01 CO CO13059928A patent/CO6690783A2/es not_active Application Discontinuation
- 2013-04-01 CU CU2013000050A patent/CU20130050A7/es unknown
- 2013-04-01 EC ECSP13012538 patent/ECSP13012538A/es unknown
- 2013-04-01 CR CR20130147A patent/CR20130147A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013538840A (ja) | 2013-10-17 |
MA34553B1 (fr) | 2013-09-02 |
EA201300420A1 (ru) | 2013-09-30 |
WO2012041987A1 (en) | 2012-04-05 |
CL2013000881A1 (es) | 2013-09-13 |
AU2011310532A8 (en) | 2014-02-20 |
GT201300085A (es) | 2015-02-16 |
CU20130050A7 (es) | 2013-07-31 |
PE20140165A1 (es) | 2014-02-26 |
CN103228274A (zh) | 2013-07-31 |
AP2013006834A0 (en) | 2013-04-30 |
US9381177B2 (en) | 2016-07-05 |
AU2011310532B2 (en) | 2016-01-14 |
AU2011310532A1 (en) | 2013-04-18 |
CA2813069A1 (en) | 2012-04-05 |
SG189038A1 (en) | 2013-05-31 |
DOP2013000070A (es) | 2014-07-15 |
CO6690783A2 (es) | 2013-06-17 |
CR20130147A (es) | 2013-05-29 |
UA112163C2 (uk) | 2016-08-10 |
US20130261120A1 (en) | 2013-10-03 |
KR20130099117A (ko) | 2013-09-05 |
ECSP13012538A (es) | 2013-06-28 |
IL225400A0 (en) | 2013-06-27 |
BR112013007835A2 (pt) | 2016-06-28 |
NZ608584A (en) | 2015-07-31 |
EP2621486A1 (en) | 2013-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013003695A (es) | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida. | |
TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201201680A1 (ru) | Морфолинопиримидины и их применение в терапии | |
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
WO2012007877A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
EA201490864A1 (ru) | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов | |
EA201591195A1 (ru) | Новые хинолоновые производные | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
EA201071288A1 (ru) | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина | |
EA201400358A1 (ru) | Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
MX343215B (es) | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos. | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
EA201391524A1 (ru) | Производные гликозида и их применение | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
WO2014001215A3 (en) | 3-o-heteroaryl-ingenol | |
EA201390488A1 (ru) | Новые агонисты gpr 119 | |
TN2013000141A1 (en) | Substituted n-(2-arylamino) aryl sulfonamide-containing combinations |